MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico-Reference-Cited by-同舟云学术

MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico

Published:2018-01-03 Issue:2 Volume:14 Page:386-395
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Cruz-Valdez Aurelio¹,Valdez-Zapata Gabriel²,Patel Sanjay S.³,Castelli Flavia V.⁴,Garcia Marcia G.⁵,Jansen Wim T.⁶,Arora Ashwani Kumar⁷,Heijnen Esther⁸

Affiliation:

1. Center of Investigation of Public Health, National Institute of Public Health, Cuernavaca, Morelos, México

2. Department of Pediatric Investigation, UNAMIS, Mérida, Yucatán, México

3. Influenza Vaccines Development, Novartis Influenza Vaccines, Cambridge, MA, USA

4. Vaccines R&D, GSK, Bs.As., Argentina

5. Vaccines R&D, GSK, Mexico City, México

6. Department of BioStatistics GSK, Amsterdam, The Netherlands

7. Clinical Development, Novartis Vaccines, Siena, Italy

8. Seasonal Influenza Vaccines, Seqirus, Amsterdam, The Netherlands

Publisher

Informa UK Limited

Subject